Austin, Texas

Austin, Texas 78759

3 studies enrolling now · 10 studies all time

What they study most

Alopecia Areata, BRVO - Branch Retinal Vein Occlusion, Branch Retinal Vein Occlusion (BRVO), Diabetic Macular Edema (DME), Healthy Participants, Idiopathic Hypersomnia, Narcolepsy Type 1, Narcolepsy Type 2, Neovascular Age-Related Macular Degeneration (NVAMD), Neovascular Age-related Macular Degeneration (NVAMD), Panic Disorder, Schizophrenia

Studies at this site

• A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO — Recruiting now
• A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia — Recruiting now
• A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia — Recruiting now
• A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration — Running, not enrolling
• A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA) — Running, not enrolling
• A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder — Stopped early
• A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia — Completed
• A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia — Completed
• A Trial to Assess the Absorption, Metabolism, Excretion, and Mass Balance of [14C]-Darigabat After a Single Oral Dose in Healthy Male Participants — Completed
• A Study to Assess Mass Balance, Pharmacokinetics, Metabolism, and Excretion of Emraclidine in Healthy Adult Male Participants — Completed